Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	43.93B
Revenue (ttm)	28.13B
Net Income (ttm)	1.28B
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	34.37
Forward PE	n/a
Dividend	1.18 (4.39%)
Ex-Dividend Date	Mar 28, 2025

Volume	1,075
Average Volume	572
Open	27.27
Previous Close	27.19
Day's Range	27.27 - 27.50
52-Week Range	23.37 - 27.50
Beta	n/a
RSI	69.46
Earnings Date	May 8, 2025

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 49,281
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2023, FRA:TKD's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY